Clinical Genomics

Clinical Genomics
-0 %
Besorgungstitel - wird vorgemerkt | Lieferzeit: Besorgungstitel - Lieferbar innerhalb von 10 Werktagen I

Unser bisheriger Preis:ORGPRICE: 153,00 €

Jetzt 126,49 €*

Alle Preise inkl. MwSt. | Versandkostenfrei
Artikel-Nr:
9780124047488
Veröffentl:
2014
Erscheinungsdatum:
07.11.2014
Seiten:
488
Autor:
Shashikant Kulkarni
Gewicht:
1611 g
Format:
289x225x30 mm
Sprache:
Englisch
Beschreibung:

Dr. Shashikant Kulkarni is the Head of Clinical Genomics, Genomics and Pathology Services and also the Director of Cytogenomics and Molecular Pathology at Washington University School of Medicine. In addition, he is Associate Professor of Pathology and Immunology, Pediatrics, and Genetics. His lab's principle research interest is delineation of novel genomic structural and single nucleotide variants in cancer.Dr. Somak Roy is an Assistant Professor, in the division of Molecular and Genomic Pathology, at the University of Pittsburgh Medical Center, in Pittsburgh, PA. He is also Director of Molecular Informatics and the Director of the MGP Fellowship Program, and Associate Laboratory Director of the Division of Molecular and Genomic Pathology. Dr. Roy's research is focused on understanding mechanisms of urothelial carcinogenesis and metastasis using next generation sequencing and microarray technologies. He also develops biomedical informatics solutions for optimizing clinical laboratory operations and quality management.

Clinical Genomics provides an overview of the various next-generation sequencing (NGS) technologies that are currently used in clinical diagnostic laboratories. It presents key bioinformatic challenges and the solutions that must be addressed by clinical genomicists and genomic pathologists, such as specific pipelines for identification of the full range of variants that are clinically important.

This book is also focused on the challenges of diagnostic interpretation of NGS results in a clinical setting. Its final sections are devoted to the emerging regulatory issues that will govern clinical use of NGS, and reimbursement paradigms that will affect the way in which laboratory professionals get paid for the testing.



  • Simplifies complexities of NGS technologies for rapid education of clinical genomicists and genomic pathologists towards genomic medicine paradigm
  • Tried and tested practice-based analysis for precision diagnosis and treatment plans
  • Specific pipelines and meta-analysis for full range of clinically important variants

Section 1: Methods

  1. Overview of technical aspects and chemistries of NGS: Dr Robi Mitra, Washington University School of Medicine.
  2. Non-selective methods (genome-wide): Dr Mark Bogoski, Harvard Medical School
  3. Capture based methods (exome, panels) Dr Birgit Funke, Harvard Medical School
  4. Amplification based methods (panels): Dr Madhuri Hegde, Emory Medical School
  5. Emerging technologies (Nanopore and others); impact on cost and turnaround time: Dr Elaine Mardis, Washington University School of Medicine.
  6. Section 2: Bioinformatics

  7. Base calling and alignment; quality metrics; depth of coverage: Dr Carl Volkerding, University of Utah, ARUP labs
  8. Single nucleotide variants (SNVs): Dr David Spencer, Washington University School of Medicine
  9. Insertions and deletions (Indels): Drs Eric Duncavage and Haley Abel, Washington University School of Medicine
  10. Large structural alterations (big deletions, translocations, and so on): Dr Charles Mullighan, St Jude's Cancer Institute
  11. Copy number variants (CNVs): Dr Mary-Claire King, University of Washington
  12. Section 3: Interpretation

  13. Reference data bases for disease associations: Dr Heidi Rehm, Harvard Medical School
  14. Reporting of results; level of evidence for associations; classes of associations: Dr Shashikant Kulkarni, Washington University School of Medicine
  15. Constitutional diseases (with individual chapters on hypertrophic cardiomyopathy, congenital deafness, blindness, cancer syndromes, and so on): Dr David Bick and Dr David Dimmock, Medical College of Wisconsin
  16. Cancer (with individual chapters on leukemia, lymphoma, lung cancer, colon cancer, and so on): Dr John Pfeifer, Washington University School of Medicine
  17. Section 4: Regulatory Issues

  18. Assay validation: Dr Ira Lublin, CDC and Dr Elizabeth Mansfield FDA
  19. QA/QC/PT issues: Dr Elaine Lyon, University of Utah, ARUP labs
  20. Consent and privacy issues: Dr James DuBois, Albert Gnaegi Center for Health Care Ethics
  21. Section 5: Reimbursement

  22. Billing: Andrew Drury and Kris Rickoff, Washington University School of Medicine

Kunden Rezensionen

Zu diesem Artikel ist noch keine Rezension vorhanden.
Helfen sie anderen Besuchern und verfassen Sie selbst eine Rezension.